You are here

Article Text

Article menu
Download PDFPDF
Brief Communication
High-dose medroxyprogesterone acetate in advanced ovarian cancer
  1. M. A. Quinn,
  2. R. M. Rome,
  3. P. Grant and
  4. R. S. Planner
  1. Royal Women's Hospital and Mercy Hospital, Melbourne, Australia
  1. Address for correspondence: Department of Gynecologic Oncology, Royal Women's Hospital, Grattan Street, Carlton, Victoria, 3053 Australia.

Abstract

Seventeen patients with advanced ovarian malignancy were treated with high-dose medroxyprogesterone acetate. No objective responses were achieved. Four patients had stable disease, one of whom remains alive with disease at 30+ months.

  • hormone therapy
  • ovarian cancer

https://doi.org/10.1111/j.1525-1438.1991.tb00047.x

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.